TD Cowen initiated coverage on Jasper Therapeutics
$JSPR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TD Cowen initiated coverage of Jasper Therapeutics with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $38.00 | Buy | UBS |
| 12/6/2024 | $63.00 | Outperform | BMO Capital Markets |
| 9/9/2024 | $70.00 | Mkt Outperform | JMP Securities |
| 7/8/2024 | $90.00 | Buy | BTIG Research |
| 6/27/2024 | $86.00 | Buy | Stifel |
| 5/6/2024 | $65.00 | Buy | H.C. Wainwright |
| 4/3/2024 | $65.00 | Outperform | Evercore ISI |
| 3/28/2024 | $70.00 | Outperform | RBC Capital Mkts |